Dogwood Therapeutics' Q3 net loss widens on higher R&D costs

Dogwood Therapeutics

06/11/2025 13:53

Overview

Dogwood Q3 net loss widens to $15.7 mln, driven by increased R&D expenses

Research and development expenses rose significantly due to SP16 licensing costs

Company secured exclusive license for SP16 in an all-stock transaction

Outlook

Final data for Halneuron expected in the second half of 2026

SP16 Phase 1b study to commence after FDA consultation

Result Drivers

Research and development expenses for the third quarter of 2025 were $14.5 million, compared to $0.5 million for the third quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$8.20
Q3 Net Income
-$15.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Dogwood Therapeutics Inc is $13.00, about 57.2% above its November 5 closing price of $5.56

Press Release: ID:nGNX7FrmL

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)